UGT2B17 and prostate carcinoma: According to previous reports, up to 44% of the patients had a deletion of UGT2B17 in Chinese HBV affected HCC samples [4], and deletion of this gene was reported to be associated with increased prostate cancer risk, TP53 mutation, and relapse of head and neck carcinoma.